The Dutch Competition Authority fines a medicine supplier on account of excessive pricing (Leadiant)

The Dutch competition authority, Autoriteit Consument & Markt (ACM), announced on Tuesday that it imposed a fine of EUR 19,569,500 on Leadiant which was found guilty of an abuse of dominant position by charging excessive prices for chenodeoxycholic acid Leadiant (“CDCA”), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Michael Clancy, Samuel Hall, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The Dutch Competition Authority fines a medicine supplier on account of excessive pricing (Leadiant), 20 July 2021, e-Competitions July 2021, Art. N° 101794

Visites 272

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues